Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Article excerpt
Highlighted: the sentence this signal was extracted from
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL ), a company improving health through innovative tests that guide patient care, today announced that it has been approved to have its common stock dually listed on Nasdaq Texas, a new exchange headquartered in Dallas. Castle will maintain its primary listing on The Nasdaq Global Market, and its common stock is expected to begin listing on Nasdaq Texas today under its existing ticker symbol, "CSTL." "Castle was founded in Texas and remains deeply connected to the state's communities, talent and innovation ecosystem," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Our dual listing on Nasdaq Texas is an important reflection of those roots and our continued commitment to supporting Texas' growth as a hub for life sciences innovation while serving clinicians and patients through our portfolio of advanced testing solutions." "Castle Biosciences is the kind of company Nasdaq Texas was built for: innovative, growth-oriented and forward-looking in every sense. We're proud to partner with a Texas-rooted leader that's making a meaningful impact on healthcare and helping prove that the future of innovation is being built right here in Texas," said Rachel Racz, president of Nasdaq Texas. Nasdaq Texas is a newly established exchange designed to support public...
Keep reading with a free account
The rest of this article, and every signal for Nasdaq, is in your free account.
